Femasys Inc., represented by the stock ticker FEMY, is a known name in the healthcare technology industry. Established in 2008 and headquartered in Atlanta, Georgia, the company specializes in developing groundbreaking technology and solutions for women's healthcare. Its primary focus pertains to reproductive health issues, aimed towards giving women the power and agency to take control of their reproductive health.
Femasys' innovative products are changing women's healthcare globally. Its product portfolio includes FemBloc™, a permanent contraceptive solution, NextGen™ Intrauterine Device (IUD), a non-hormonal long-term contraceptive method, and the FemaSeed, which is the first known directed insemination device that provides women with a more natural and personal fertility solution.
One of the leading developments by Femasys is FemBloc™, a non-surgical permanent contraceptive solution that could potentially replace traditional, invasive tubal ligation surgeries. It is designed to be a safer, simpler, and more convenient solution for women seeking permanent contraception. This innovation offers a less invasive alternative that can be delivered in a physician's office without the need for general anesthesia.
Femasys' NextGen™ Intrauterine Device (IUD) offers long-term reversible contraception for up to 10 years, an alternative to more commonly used hormonal options. This copper-based IUD emphasizes accessibility and affordability without compromising safety and efficiency, making it a strong contender in the global contraceptive market.
In the fertility space, Femasys’ FemaSeed provides an innovative potential solution to in-vitro fertilization (IVF). By simulating natural conception, it aims to offer women a more natural and personal fertility solution that reduces the need for the clinical and invasive procedures involved in traditional IVF.
As a pioneer in women’s healthcare, Femasys has shown commitment to delivering innovative solutions for unmet and underserved needs. However, like all companies in the medical technology space, Femasys needs to navigate intense scrutiny from regulatory bodies and the pressures of the healthcare landscape. Despite these challenges, Femasys has demonstrated its ability to constantly innovate and create valuable solutions in the women's healthcare sector. The company thus stands strong as an important force in the global healthcare technology industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Femasys, Inc. announced that the FDA has authorized the modular premarket approval application pathway for FemBloc, its non-surgical permanent birth control technology, which is designed for in-office delivery and avoids surgery and anesthesia. Despite this regulatory milestone, Femasys' stock is in a bearish trend, with significant declines over the past year, though it saw a 24.09% increase at the time of publication on Wednesday.
Femasys Inc. (NASDAQ: FEMY) has secured FDA authorization for a modular premarket approval pathway for FemBloc, its non-surgical permanent birth control technology. This device offers an office-based alternative to surgical sterilization, utilizing a blended polymer to create a permanent occlusion in the fallopian tubes without anesthesia or incisions. Despite this regulatory milestone, the company's stock has shown a significant bearish trend over the past 12 months, with a substantial decline in value.
Femasys has received FDA approval for a modular premarket approval (PMA) pathway for FemBloc, its non-surgical permanent birth control technology. This approval allows Femasys to submit portions of its regulatory application for review while the pivotal U.S. clinical trial, FINALE, is still ongoing. The company plans to leverage its existing commercial team for fertility products to support FemBloc's potential U.S. launch, following its previous regulatory approvals in Europe, the UK, and New Zealand.